How a niche Indian topicals manufacturer outgrew its CDMO roots, bought a Sanofi icon, and became the hottest target in the Warburg-Mubadala deal room
In June 2021, when Quadria Capital valued Encube Ethicals at ~$800 million, it was considered a fair price for a solid, single-site CDMO with USFDA credentials.
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
